Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.
Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.
Coherus Oncology (CHRS) reported Q3 2025 results. Continuing operations net revenue was $11,571, driven by LOQTORZI revenue of $11,169. Loss from continuing operations was $(44,517). Discontinued operations contributed net income of $8,986, resulting in a quarterly net loss of $(35,531).
The company closed the divestiture of the UDENYCA franchise on April 11, 2025 for upfront cash of $483.4 million, recognizing a net gain of $338.7 million. Proceeds were used to redeem substantially all 2026 convertible notes and to buy out UDENYCA royalty rights for $47.7 million.
As of September 30, 2025, cash and cash equivalents were $103,352 and investments in marketable securities were $88,311. Total assets were $516,519, total liabilities $428,745, and stockholders’ equity was $87,774. Shares outstanding were 116,236,018 at quarter end.
Coherus Oncology, Inc. (CHRS) reported that it furnished, not filed, a press release announcing financial results for the fiscal quarter ended September 30, 2025. The company disclosed this under Item 2.02 and attached the full text as Exhibit 99.1.
The submission clarifies that the information provided under Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference unless specifically stated. The filing also includes the Cover Page Inline XBRL as Exhibit 104.
Coherus Oncology, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing. The company previously received a Nasdaq deficiency notice on June 30, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days, giving it until December 29, 2025 to cure the issue.
On September 5, 2025, Nasdaq informed Coherus that the closing price of its common stock had been $1.00 or greater for the requisite period, restoring compliance with Listing Rule 5550(a)(2). Coherus is now in full compliance with all continued listing standards of the Nasdaq Global Market, removing the immediate risk associated with the prior deficiency notice.